SG11201406455YA - SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT - Google Patents

SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT

Info

Publication number
SG11201406455YA
SG11201406455YA SG11201406455YA SG11201406455YA SG11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA
Authority
SG
Singapore
Prior art keywords
sorcs1
overweight
obesity
treatment
Prior art date
Application number
SG11201406455YA
Inventor
Karen-Marie Pedersen
Anders Nykjaer
Mads Fuglsang Kjølby
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Publication of SG11201406455YA publication Critical patent/SG11201406455YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201406455YA 2012-04-17 2013-04-17 SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT SG11201406455YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201270191 2012-04-17
PCT/DK2013/050107 WO2013156031A2 (en) 2012-04-17 2013-04-17 SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT

Publications (1)

Publication Number Publication Date
SG11201406455YA true SG11201406455YA (en) 2014-11-27

Family

ID=49384162

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406455YA SG11201406455YA (en) 2012-04-17 2013-04-17 SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT

Country Status (10)

Country Link
US (1) US20150166629A1 (en)
EP (1) EP2874646A4 (en)
JP (1) JP2015514726A (en)
CN (1) CN104470532A (en)
AU (1) AU2013248727A1 (en)
CA (1) CA2870211A1 (en)
HK (1) HK1208159A1 (en)
IL (1) IL235066A0 (en)
SG (1) SG11201406455YA (en)
WO (1) WO2013156031A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136781B (en) * 2015-08-13 2018-03-30 上海交通大学医学院附属瑞金医院 Applications of the Adipocyte Factor GREM2 as drug target in obesity treating medicine
EP3666281A1 (en) 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AT404357B (en) * 1995-06-13 1998-11-25 Immuno Ag PROTHROMINE DERIVATIVES
AU782580B2 (en) * 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
EP1554397A4 (en) * 2002-09-09 2006-06-21 Wisconsin Alumni Res Found Type 2 diabetes susceptibility genes
HUE031611T2 (en) * 2006-12-21 2017-07-28 H Lundbeck As Modulation of activity of proneurotrophins
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
DK2440233T3 (en) * 2009-06-10 2016-11-07 Univ Aarhus SorCS1-like means for use in the treatment of insulin resistance and diseases associated therewith

Also Published As

Publication number Publication date
AU2013248727A1 (en) 2014-11-06
JP2015514726A (en) 2015-05-21
HK1208159A1 (en) 2016-02-26
EP2874646A2 (en) 2015-05-27
US20150166629A1 (en) 2015-06-18
CN104470532A (en) 2015-03-25
WO2013156031A2 (en) 2013-10-24
EP2874646A4 (en) 2016-07-06
IL235066A0 (en) 2014-12-31
WO2013156031A3 (en) 2013-12-12
CA2870211A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
IL282128A (en) Methods of treating overweight and obesity
HK1216176A1 (en) Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
IL237125A0 (en) Niclosamide and its derivatives for use in the treatment of solid tumors
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
HRP20181879T1 (en) Compounds for the treatment of obesity and methods of use thereof
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
IL233875A (en) Composition and use thereof in the treatment of anal rhagades
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
LT2845598T (en) Preparation for use in the prophylaxis and treatment of atypical osteoporosis
EP2744786A4 (en) Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer
HK1208159A1 (en) Sorcs1 for use in the treatment of obesity and overweight sorcs1
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
SI2663185T1 (en) Calebin a for use in the treatment of inflammation and obesity
PT2389936E (en) Aminaphtone for use in the treatment and/or prevention of migraine
GB201117876D0 (en) Peptides and their use in treatment
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer